Evidence map›Paper›PMID 34608355›Full record

ReviewMRS bulletin2021

Rapid growth in the COVID-19 era.

Yerim Lee, Michelle Ng, Kristin Daniel, Elizabeth Wayne

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in MRS bulletin, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Vaccine Innovation Meta-Model for Pandemic Contexts.Journal of pharmaceutical innovation · 2023
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yerim Lee *Department of Biomedical Engineering, and Department of Chemical Engineering, Carnegie Mellon University, Pittsburgh, PA USA.
Michelle Ng *Department of Biomedical Engineering, and Department of Chemical Engineering, Carnegie Mellon University, Pittsburgh, PA USA.
Kristin Daniel *Department of Biomedical Engineering, and Department of Chemical Engineering, Carnegie Mellon University, Pittsburgh, PA USA.
Elizabeth WayneDepartment of Biomedical Engineering, and Department of Chemical Engineering, Carnegie Mellon University, Pittsburgh, PA USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractFrom Operation Warp Speed to the lipid mRNA vaccine, the COVID-19 pandemic has been a watershed moment for technological development, production, and implementation. The scale and pace of innovation and global collaboration has likely not been experienced since World War II. This article highlights some of the engineering accomplishments that occurred during the pandemic. We provide a broad overview of the technological achievements in vaccine design, antibody engineering, drug repurposing, and rapid diagnostic testing. We also discuss what the future of these technologies and the future of large-scale collaborations might look like moving forward. GRAPHIC ABSTRACT:

Indexed as

Drug repurposingmRNA lipid nanoparticle vaccineOperation WARP speedRapid-antigen detectionTherapeutic antibodies

Identifiers

PMID34608355
PMCPMC8480751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.